Clinical trials in nuclear medicine. Sorted by date of last update.
Testing Lutetium Lu-177 Dotatate in Patients with Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
Phase 2
Last update: October 10
Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients with Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH
Phase 4
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (Lu-177) Vipivotide Tetraxetan in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
Phase 1
Lu-177-DOTA-EB-TATE in Adult Patients with Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study
Lu-177-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer (PSMAfore)
Phase 3
Last update: October 9
A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (Lu-177) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults with Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study (RADIODOSE)
Last update: October 8
Study of RYZ101 Compared with SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following Lu-177-SSA Therapy (ACTION-1)
A Study of [Lu-177]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination with Carboplatin, Etoposide and Atezolizumab